2. Anti-infection NF-κB Apoptosis
  3. Influenza Virus Fungal NF-κB Apoptosis
  4. Hyperoside

Hyperoside 

Cat. No.: HY-N0452 Purity: 99.56%
COA Handling Instructions

Hyperoside is a NF-κB inhibitor, found from Hypericum monogynum. Hyperoside shows anti-tumor, antifungal, anti-inflammatory, anti-viral, and anti-oxidative activities, and can induce apoptosis.

For research use only. We do not sell to patients.

Hyperoside Chemical Structure

Hyperoside Chemical Structure

CAS No. : 482-36-0

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solution
10 mM * 1 mL in DMSO USD 61 In-stock
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
 USD 61 In-stock
Solid
5 mg USD 55 In-stock
10 mg USD 88 In-stock
20 mg USD 154 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 4 publication(s) in Google Scholar

Hyperoside Related Antibodies

Top Publications Citing Use of Products

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Hyperoside is a NF-κB inhibitor, found from Hypericum monogynum. Hyperoside shows anti-tumor, antifungal, anti-inflammatory, anti-viral, and anti-oxidative activities, and can induce apoptosis[1][2].

In Vitro

Hyperoside (12.5-100 μM; 6-24 h) inhibits MCF-7 and 4T1 cell growth[2].
Hyperoside (25-100 μM; 24 h) induces apoptosis of breast cancer cells[2].
Hyperoside inhibits the activation of the NF-κB signaling pathway via the attenuation of intracellular ROS generation[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Hyperoside Related Antibodies

Cell Viability Assay[2]

Cell Line: MCF-7 and 4T1 cells
Concentration: 12.5, 25, 50, 75, or 100 µM
Incubation Time: 6, 12, or 24 h
Result: Inhibited cell growth in a time- and concentration-dependent manner.

Apoptosis Analysis[2]

Cell Line: MCF-7 and 4T1 cells
Concentration: 25, 50 and 100 µM
Incubation Time: 24 h
Result: Increased the expressions of Bax, cleaved caspase-3 and cleaved PARP, and decreased Bcl-2 in mRNA and protein levels.
In Vivo

Hyperoside (intraperitoneal injection; 50 mg/kg; every two day for 18 days) treatment inhibits breast tumor growth in vivo[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Balb/c mice injected with 4T1 cells[2]
Dosage: 50 mg/kg
Administration: Intraperitoneal injection; 50 mg/kg; every two day for 18 days
Result: Reduced the average tumor volume compared to the control group.
Decreased Bcl-2 and increased bax and cleaved caspase-3.
Molecular Weight

464.38

Appearance

Solid

Formula

C21H20O12
CAS No.
SMILES

OC1=CC(O)=C(C(C(O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)=C(C3=CC=C(O)C(O)=C3)O4)=O)C4=C1
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 125 mg/mL (269.18 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1534 mL 10.7670 mL 21.5341 mL
5 mM 0.4307 mL 2.1534 mL 4.3068 mL
10 mM 0.2153 mL 1.0767 mL 2.1534 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  50% PEG300    50% saline

    Solubility: 10 mg/mL (21.53 mM); Clear solution; Need ultrasonic

  • 2.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (4.48 mM); Clear solution

  • 3.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (4.48 mM); Clear solution

*All of the co-solvents are available by MCE.
Purity & Documentation

Purity: 99.56%

COA (257 KB) HNMR (320 KB) LCMS (96 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Hyperoside Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

Hyperoside482-36-0Influenza VirusFungalNF-κBApoptosisNuclear factor-κBNuclear factor-kappaBanti-tumor activityantifungal activityanti-inflammatory activityanti-viral activityand anti-oxidative activityinduce apoptosisMCF-74T1Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Hyperoside
Cat. No.:
HY-N0452
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email address *

Phone number

 

Department *

Organization name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.